Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

NewsGuard 100/100 Score

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body. The unique ability to inhibit and block the harmful effects of Galectin-3 is one of MCP's many essential health benefits.

This extensive body of research was presented to hundreds of naturopathic oncologists at the Oncology Association of Naturopathic Physicians (OncANP) 2012 Convention & Exposition.

"It's truly rewarding to share cutting-edge research demonstrating Modified Citrus Pectin's ability to promote health and prevent disease," says Dr. Eliaz.

Galectin-3 is a protein produced naturally by our bodies, but elevated levels can lead to chronic inflammation, fibrosis, heart disease, and metastatic cancer. By binding and blocking excess Galectin-3, Modified Citrus Pectin (www.mcprecommends.com) prevents this rogue protein from wreaking havoc.

The FDA recently approved a blood test that measures Galectin-3 levels, highlighting a key risk factor for progressive heart failure. The test can also determine Galectin-3 induced risk to the liver, lungs, brain and kidneys, as well as indicate risks of cancer progression and metastasis.

Versatile Health Benefits of MCP
Recent studies demonstrate that Modified Citrus Pectin significantly enhances immune function, and reduces galectin-3 expression and disease severity in kidney injury. Furthermore, MCP is proven through multiple clinical studies to remove lead, mercury, arsenic, and cadmium from the body without reducing essential minerals.

Dr. Eliaz also shared new research showing that MCP, when combined with two advanced poly-botanical formulas, works synergistically to inhibit aggressive breast and prostate cancer cells. This study was presented at the last Experimental Biology meeting and is currently in press for publication.

"Researchers found that MCP, in combination with either the breast or prostate formula, further inhibits the metastatic processes of adhesion and migration of breast and prostate cancer cells," says Dr. Eliaz.

These new discoveries demonstrate that Modified Citrus Pectin (www.mcprecommends.com) can potentially help address many serious health conditions which currently have limited or no treatment options.

Honokiol for Cancer and Anti-Anxiety Support
Dr. Eliaz concluded this presentation by sharing research on the botanical compound, Honokiol. The data presented by Dr. Eliaz demonstrates that Honokiol provides many health benefits as an anti-cancer, anti-oxidant and anti-anxiety agent. Honokiol is a Magnolia bark extract and is safe to use with conventional cancer therapies. Honokiol has also been shown to work synergistically with Modified Citrus Pectin, to increase anti-cancer support.

OncANP is one of the largest naturopathic oncology organizations. The association provides advanced training in naturopathic oncology to improve quality of care and patient outcome.

Source:

 Better Health Publishing

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NCCN 2024 Annual Conference focuses on practical applications for improving cancer care